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ABSTRACT 
Immunoglobulin A deficiency (IgAD) is the most common primary immunodeficiency in 
Caucasian populations. It is defined as a serum IgA level below 0.07 g/L with normal IgM 
and IgG levels in an individual older than four years of age. Approximately one-third of 
these patients present with recurrent respiratory and gastrointestinal tract infections, allergic 
disorders and autoimmune manifestations. High familial clustering and prevalence variation 
by ethnicity both suggest the existence of a strong genetic component of the disease. 
Traditionally, IgAD has been reported as permanent, and sub-normal IgA levels remain static 
and persist after 20 years of observation. However, a few cases of reversion have been 
observed. We thus investigated the frequency of reversal in children and more than one-fifth 
(>20%) of Swedish children who were diagnosed before 10 years of age, reversed their IgAD 
status. Our observation suggests that the diagnosis of IgAD should not be made before the 
early teens using a cutoff level of 0.07 g/L of IgA in serum.  
After suggesting improved diagnostic guidelines, we investigated the role of genetics in IgAD 
in a Swedish Twin cohort. Surprisingly, the prevalence of IgAD was found to be markedly 
increased in a twin cohort as compared with the normal Swedish adult population. Although 
the MHC is the main genetic factor associated with IgAD development, the MHC haplotypes 
were not the primary factor causing the differences observed. Nonetheless, risk-conveying 
MHC haplotypes including HLA-A*01, HLA-B*08 and HLA-DRB1*01 were found to be 
associated with significantly lower serum IgA concentration in the twin cohort. On the 
contrary, individuals who carried the protective HLA alleles B*07, DRB1*15 and 
DQB1*06 were found to have significantly higher mean IgA concentration.  
We then performed a comprehensive analysis within the MHC region in order to identify the 
potential susceptibility genes/loci within the MHC region. In our large-scale case-control 
study, we identified an independent MHC haplotype (HLA-DPB1*1301) in the class II region 
associated with IgAD. In addition, MHC recombination analysis suggested a region around 
110 Kbp which may contain a portion of the ancestral block. However, verification using 
complete sequencing did not identify any differences. Nonetheless, identification of 4310 
new variants from ancestral 8.1 haplotypes will provide valuable information for the 
investigation of other MHC associated diseases. We also identified novel genes/variants 
within the MHC class III region including AGER (rs1800625), RNF5 (rs3130349), BTNL2 
(rs1980493) and HCG23 (rs3117097) that are associated with IgAD risk.  
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Subsequently, we investigated the association of non-MHC genes using different MHC risk 
haplotypes as category factors. In total, 14 different genes/loci were identified as potentially 
associated with IgAD in individuals carrying different MHC risk alleles, including one from 
HLA-B*0801-DRB1*0301-DQB1*0201 (ancestral haplotype), three from the HLA-
DRB1*0701-DQB1*0202 cohort, two from HLA-DRB1*01-DQB1*0501 and seven from 
patients who do not carry any susceptibility MHC allele. These findings suggest that the 
development of IgAD may be variable depending on the presence of potentially different 
genes within selected MHC susceptibility haplotypes that interact with the respective disease-
causing non-MHC genes. Understanding the interaction between MHC and non-MHC genes 
and proteins may facilitate identification of the IgAD etiology. 
In summary, this thesis not only helped to identify the genetic basis of IgAD, but also 
improved the current diagnostic definition of the disease. Further work, including protein-
protein interaction investigations, gene knock-in/out and expression analyses are required to 
validate the functional role of the novel associations described in this thesis. As IgAD has 
been shown to be markedly overrepresented among patients with autoimmune diseases, 
further potential studies will aim to identify the link between IgAD and autoimmunity 
which may ultimately result in improved patient care. 
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1 INTRODUCTION 
1.1 Immunoglobulin A 
Immunoglobulin A (IgA) is the predominant antibody class in mucosal secretions and is the 
second most prevalent antibody in serum after IgG (1). IgA comprises at least 70 % of all 
immunoglobulins produced in the human body and plays a key role in immunity.  
There are two IgA subclasses in humans, which are encoded by two functional genes, 
resulting in two IgA subclasses (IgA1 and IgA2, Figure 1). The length of the hinge region 
is the major difference between IgA1 and IgA2 (1, 2).  
Whilst serum IgA predominantly consists of monomeric IgA1, secretory IgA (S-IgA) 
(Figure 1) is chiefly polymeric, comprising mainly dimeric forms, with an increased 
proportion of IgA2 (2). Serum IgA is produced by B-lymphocytes in the bone marrow 
while S-IgA is synthesized locally at the mucosal surfaces (2). There is a strong correlation 
between serum IgA concentrations and mucosal IgA concentrations (3).  
The function of S-IgA is to protect the lining of the respiratory, gastrointestinal and 
genitourinary tracts from invading pathogens by neutralizing antigens as well as preventing 
the adherence of bacteria (2, 4, 5). On the other hand, the function of serum IgA is less clear, 
although there are reports of its involvement in triggering effector functions (2, 6). 
In Swedish adults (>20 years old), the normal range of serum IgA levels for adults is 0.88-
4.5 g/L (reference range at the Karolinska University Hospital Clinical 
Immunology/Transfusion Medicine Laboratory, Sweden). 
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1.2 IMMUNOGLOBULIN A DEFICIENCY (IGAD) 
Immunoglobulin A deficiency (IgAD) is the most common human primary antibody 
deficiency in Caucasian populations. It is defined as a serum IgA level below or equal to 0.07 
g/L in the presence of normal levels of other immunoglobulin isotypes in an individual older 
than four years of age (7-9).  
IgAD comprises a heterogeneous group of disorders, ranging from asymptomatic 
(incidentally noted in healthy blood donors) to symptomatic patients presenting with different 
clinical phenotypes, including recurrent infections of the gastrointestinal and respiratory 
tracts, allergic disorders and autoimmune diseases of variable severity (10-14). In addition, 
recent reports have shown that patients with IgAD have significantly poorer physical health 
and an increased risk of early death (15, 16). 
The prevalence of IgAD is variable in different populations, ranging from 1:143 in Saudi 
Arabia (17)  to 1:18500 in Japan (18). However, the prevalence may be underestimated 
because some individuals with IgAD are asymptomatic, and established routine screening 
programs for IgAD are rare, particularly in Asia. Up to 40% of IgAD patients develop anti-
IgA antibodies (19). From a transfusion medicine perspective, the presence of anti-IgA 
antibodies in an IgA deficient recipient is a possible cause of anaphylactic transfusion 
reaction. Approximately 20% of anaphylactic transfusion reactions in Western populations 
are associated with anti-IgA antibodies in IgA deficient recipients (20).  
Since the prevalence varies widely between different populations, this supports the view that 
genetic factors play an essential role in the pathogenesis of the disease. In addition, the 
observation of familial clustering, as well as associations with known genetic loci have 
provided clinical evidence for the genetic predisposition to IgAD. However, the exact 
etiology of IgAD remains unclear.  
1.3 MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) 
The major histocompatibility complex (MHC) locus is an extremely polymorphic region and 
has been one of the most intensively investigated areas in the human genome. In humans, the 
MHC is called the human leukocyte antigen (HLA) as the gene products were initially 
identified using alloantibodies against leukocytes (21). This genomic region is located on 
chromosome 6p21 and spans approximately 3.6 megabase pairs (Mbp) and encodes over 200 
genes, many of which have a defined immunological function (22). An extended MHC of 7.6 
Mb comprising more than 400 annotated genes and pseudogenes has also been described 
more recently (23).   
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The MHC complex contains two primary classes, the MHC class I and MHC class II gene 
clusters. The MHC class I molecules are expressed on the surface of all nucleated cells, 
whereas the expression of MHC class II molecules is restricted to antigen presenting cells, 
such as B cells and dendritic cells. The MHC class II molecules are responsible for 
presenting peptide antigens to T cells, thereby initiating the adaptive immune responses. In 
addition, there is an MHC class III region which spans the region between the MHC class I 
and MHC class II gene clusters. The MHC class III region contains genes that are involved 
in immunity, such as the complement genes and genes encoding inflammatory cytokines 
(24). 
Given the central role of the MHC in immune function, in addition to its level of diversity, 
the involvement of MHC in disease susceptibility is not surprising. The importance of this 
locus to the pathogenesis of human disorders is proven by the reported association of 
polymorphisms in the HLA region with over two hundred diseases, including autoimmune 
diseases, primary immunodeficiency diseases, susceptibility to infections, malignancies and 
psychiatric conditions (25-28) (Figure 2).   
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1.4 MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) ASSOCIATIONS OF 
IGAD 
The MHC was first identified as a risk locus for IgAD through the association with HLA 
Class I and Class II markers and ascribed to specific conserved haplotypes (29-32).  Most 
notably, the HLA-B*08-DRB1*0301-DQB1*02 haplotype (ancestral 8.1) has been identified 
as the most significant genetic risk factor for IgAD in Northern European populations (33, 
34).  Thirteen percent of homozygous individuals with HLA-B*0801-DRB1*0301-
DQB1*0201 have been estimated to be IgA deficient (32), although this might be 
overestimated due to publication bias (35).  Conversely, the HLA-DRB1*1501-DQB1*06 
haplotype has been shown to confer substantial protection against IgAD, with homozygous 
individuals showing virtually complete protection from the disease (33, 34). Additionally, 
susceptibility has also been shown to be associated with two other haplotypes, i.e., HLA-
B*14-DRB1*0102-DQB1*05 and the HLA-B*44-DRB1*0701-DQB1*02 haplotypes (33, 34).  
Interestingly, a recent study from China showed that the ancestral 8.1 haplotype (HLA-B*08-
DRB1*0301-DQB1*02) is also associated with the disease in the Chinese population (36, 37).   
Despite the strong association with the HLA locus, there has been no consensus as to the 
precise location of the causal variants.  Some research groups have suggested that the location 
of the susceptibility area for IgAD is the telomeric region of MHC Class II (38-40), while 
others have proposed the centromeric region of MHC Class III (40-43).  In addition, others 
have suggested a susceptibility locus in a region of MHC Class III that encodes cytokines 
needed for immunoglobulin production, which may also be associated with other forms of 
immunodeficiency, such as common variable immunodeficiency (CVID) (32). A subgroup 
analysis has also proposed the haplotype MSH5-85F-DRB1*0102 at the telomeric end of 
MHC class II as a potential susceptibility region for IgAD (44). Furthermore, a lack of 
diversity of MHC Class II, and an amino acid (AA) substitution at position 57 of the HLA-
DQB1 chain may also be associated with the pathogenesis of  IgAD (33). 
1.5 NON-MHC ASSOCIATIONS OF IGAD 
In addition to linkage to the HLA region, IgAD has been found to be associated with variants 
within the Interferon-induced helicase C domain-containing protein 1 gene (IFIH1) as well as 
variants within the C-type lectin domain family 16 gene (CLEC16A). These genes have also 
been implicated in the susceptibility to a variety of autoimmune disorders including type 1 
diabetes (T1D), systemic lupus erythematosus (SLE) and celiac disease (CD) (45). 
Furthermore, recent findings show that common variants at PVT1, ATG13-AMBRA1 and 
AHI1 are associated with IgAD. These variants overlap with autoimmune markers and 
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correlate with 21 putative regulatory variants, such as DNase hypersensitivity sites in 
FOXP3
+
 regulatory T cells (46). 
1.6 CYTOGENIC DEFECTS IN IGAD 
Cytogenetic defects and chromosomal abnormalities have frequently been reported in patients 
with IgAD.   Significant anomalies were reported involving chromosomes 16 and 18 (47-52), 
while defects in other chromosomes have also been observed, including 4p monosomy, 
trisomy 10p, and translocation of 10q to 4p (53, 54). Long or short-arm deletion and ring 
formation have been described in some patients who exhibit additional dysmorphic features 
and are intellectually disabled (49). However, there are conflicting findings concerning the 
presence or absence of substantial chromosomal abnormalities in IgAD. A study based on 
asymptomatic IgAD individuals has not identified any chromosomal abnormalities (55). This 
observation suggests that cytogenic defects are probably not relevant to asymptomatic IgA 
deficient patients. 
1.7 MONOGENIC MUTATIONS ASSOCIATED WITH IGAD AND 
ASSOCIATION WITH OTHER PRIMARY IMMUNODEFICIENCY 
DISEASES 
The first significant monogenic mutation to be identified in IgAD was a mutation in the 
tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) / transmembrane 
activator and calcium modulator and cyclophilin ligand interactor (TACI), which mediates 
isotype switching in B cells. TACI was expressed in B cells from these patients but they did 
not produce IgA and IgG in response to the TACI ligand, suggesting impaired isotype 
switching (56, 57). TACI mutations have been seen both in patients with CVID and in those 
with IgAD, however, are only present in a small subset of patients with each disease (56, 57). 
Some IgAD cases may progress to CVID (58, 59). One study suggests that individuals with a 
C104R, A181E or ins204A variant in the TACI gene may be at risk for disease progression 
from IgAD to CVID (60). Nonetheless, it is not clear whether these mutations are causative, 
or there may be additional defects that have not yet been identified.  
Advancement of technologies such as next-generation sequencing (NGS), coupled with 
enhanced algorithms for bioinformatics has enabled a much broader approach to interrogate 
multiple genes simultaneously through one single reaction. This strategy has proven to be a 
practical approach by which to identify the genetic basis of Mendelian diseases in the clinical 
research setting. Molecular diagnostic testing using whole exome sequencing (WES) or 
whole genome sequencing (WGS) (61, 62) has greatly enhanced the discovery of new 
monogenic defects in Primary immunodeficiency diseases (PID). 
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Seven IgAD patients with a hypomorphic mutation in JAK3 and ARTEMIS (DCLRE1C) have 
been reported (63, 64). In addition, Kato et al. identified a young IgAD patient with RAG1 
deficiency (65) and Akhairy et al. recently identified two cases of IgAD progressing to CVID 
due to a mutation in the LRBA and CD27 genes, respectively (66, 67). 
In addition, some monogenic mutations in PID genes are associated with  IgAD, including 
genes that are associated with combined immunodeficiency (ATM, CHD7,  DNMT3B, DKC1,  
MLH1, MECP2, NBS1, RAD50, PMS2, PNP,  RMRP,  RNF168, TINF2,  TTC7, WAS and 
ZBTB24), antibody deficiencies (BTK, CARD11, PIK3R1, MSH2, MSH6, TACI and TWEAK), 
defects in intrinsic and innate immunity (CXCR4, IL12RB1 and STAT1) as well as genes  
associated  with  phagocytic abnormalities (CYBB,  NCF1, RAC2 and SBDS) (68, 69).  
Furthermore, loss of function mutations in several non-MHC genes have been found in 
families with IgAD in which progression occurs from a normal immunologic state to IgA 
deficiency, with or without IgG subclass deficiency or CVID (70-73).  IgAD is also reported 
to be associated with IgG2 subclass deficiency (74) and ataxia telangiectasia (75). 
Furthermore, Smith et al. reported a 13% (OR = 14.20) prevalence of  IgAD in patients with 
DiGeorge syndrome (76).  
1.8 RELATIONSHIP TO AUTOIMMUNITY 
Various autoimmune diseases are known to be associated with IgAD, including juvenile 
idiopathic arthritis (JIA), dermatomyositis, sarcoidosis, Sjögren syndrome, Evans syndrome, 
isolated hemolytic anemia, pernicious anemia, rheumatoid arthritis (RA), SLE, Graves’ 
disease (GD), T1D, CD, immune thrombocytopenic purpura (ITP), Hashimoto’s thyroiditis, 
pulmonary hemosiderosis, Addison’s disease, chronic nephritis, Henoch-Schonlein purpura 
and myasthenia gravis (MG) (77). 
The same MHC haplotypes seen in patients with IgAD were found to be associated with 
selected autoimmune disorders, including T1D, SLE, CD, RA (12) where IgAD is markedly 
overrepresented (up to 30 fold). A recent study by Abolhassani et al. showed 
that autoimmune diseases were documented in approximately 30% of IgAD cases (78). This 
observation suggested a genetic overlap between IgAD and autoimmune disorders. 
Furthermore, genome-wide association studies (GWAS) have revealed an association 
between IgAD and genetic variants in the gene for IFIH1 and CLEC16A (45). Mutations in 
these genes are also associated with autoimmune diseases, which further suggest a connection 
between IgAD and autoimmune disease. The prevalence of autoimmune disorders has been 
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observed to be increased among first degree relatives of patients with IgAD, also supporting 
this hypothesis (79). Alternatively, the other hypothesis is that the autoimmune diseases occur 
as a result of recurrent infections and multiple exposures to foreign antigens that should have 
been “neutralized” by IgA. This hypothesis is partly demonstrated by a report which showed 
the presence of antibodies against milk in patients with IgA deficiency correlated with an 
increased frequency of serum autoantibodies (80). However, the exact pathogenetic 
mechanisms remain unclear. 
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2 AIMS 
 
 
2.1 GENERAL AIM  
The aim of this thesis was to study the genetic risk factors associated with IgAD in humans.  
 
 
2.2 SPECIFIC AIMS  
 
 To investigate the frequency of IgAD reversal in a large cohort of children and 
teenagers in order to evaluate the present definition of IgAD. 
 To characterize the occurrence and concordance of IgAD in MZ and DZ twins and 
to identify MZ twin pairs discordant for IgAD for future functional studies. 
 To fully characterize the sequence of the MHC region in order to search for 
mutations/variants which cause susceptibility to IgAD.   
 
 To define etiological subgroups of IgAD using HLA risk alleles as categorical factors 
in order to identify potential causative non-MHC region markers involved in the 
pathogenesis of IgAD. 
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3 MATERIALS AND METHODS 
3.1 SAMPLE COLLECTION 
The recruitment and participation of the described Swedish patients and controls included 
in this thesis was approved by Regionala Etikprövningsnämnden i Stockholm (the regional 
ethical review board in Stockholm). 
3.1.1 Children with IgAD 
3.1.1.1 Symptomatic children 
Between 1992 and 2012, 654 children aged from 4 to 13 years who were referred for 
serological testing for investigation of gastrointestinal symptoms were identified from 
laboratory data at five university hospitals in Sweden (283 from Karolinska Hospital in 
Stockholm, 78 from Sahlgrenska hospital in Gothenburg, 149 from the University Hospital in 
Lund, 86 from the University Hospital in Linköping and 58 from the Academic Hospital in 
Uppsala) and were selected for follow up analysis.  Data from patients with multiple 
laboratory records with a minimum interval of 90 days was collected. The age of IgAD 
reversal was defined at the date of the first IgA value over 0.07 g/L or the first medical report 
indicating that IgA was detected.  The follow-up concluded on 31 Jan 2014. 
3.1.1.2 BAMSE follow up study 
Pediatric samples from a previous study (the Children, Allergy, Milieu, Stockholm, 
Epidemiological survey [BAMSE] during 1994-1996) (81) were included. In total, out of 
2423 children, 14 were identified to have IgAD at the age of 4 years (13) and this group had 
subsequently been followed up at the age of 8 years and were assessed again at 16 years of 
age.  
3.1.2 Twin samples 
For paper II, a total of 12 613 individuals (3130 MZ twins and 9483 DZ twins) were 
included in the study.  Samples were obtained from the TwinGene project, a population-
based study of Swedish twins of European ancestry born between 1911 and 1958, which 
included serum and DNA samples collected between 2004 and 2008 (82). For paper III and 
IV, 9741 Swedish twin samples (including MZ twins: 4063, one per family; DZ twins: 5678, 
two per family) from paper II were included, where 39 were identified as having IgAD 
(serum IgA < 0.07 g/L) (83). 
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3.1.3 Swedish IgAD patients and controls 
For papers III, IV, a total of 767 Swedish IgAD patients referred to the Karolinska University 
Hospital in Stockholm were included in the studies. In addition, 485 healthy Swedish 
controls, recruited from a previous study (34) were included.  
3.1.4  Multi-case family samples 
For paper IV, a total of 73 Swedish multi-case families including 162 sibling pairs who had 
been followed up in Karolinska University Hospital in Stockholm were included in the study. 
Their year of birth ranged from 1910 to 2002.   
3.2 SERUM IGA MEASUREMENT 
3.2.1 Nephelometry 
For papers I, III and IV, serum levels of IgA, IgG and IgM from the samples and controls 
were determined by nephelometry at the Karolinska University Hospital Clinical 
Immunology Laboratory, Sweden. IgAD was diagnosed if the serum IgA level was ≤ 0.07 
g/L with normal serum levels of IgG and IgM. 
3.2.2 Reverse-phase protein microarray 
For Paper II, the serum IgA concentration was measured by a reverse-phase protein 
microarray as described previously (84). Briefly, diluted serum samples were spotted onto 
epoxy-coated microarray slides (Corning, USA) using the 2470 Arrayer Microarray 
Printing Platform (Aushon Biosystems, USA). Rabbit anti-human IgA (dilution 1:100 000, 
DakoCytomation, Denmark) and Alexa Fluor 555-conjugated goat anti-rabbit antibodies 
(dilution 1: 60 000, Molecular Probes, USA) were used to detect the level of IgA. Images 
were generated using a high-resolution microarray scanner (Agilent Technologies, USA) 
and subsequently analyzed by GenePix Pro 7 (Molecular Devices, USA). 
3.2.3 Enzyme-linked immunosorbent assay (ELISA) 
 
For paper I (follow up samples) and paper II (all samples), Serum IgA levels were also 
determined by sandwich ELISA using polyclonal rabbit anti-human IgA antibodies (DAKO, 
Denmark) and alkaline phosphatase-conjugated rabbit anti-human serum IgA antibodies 
(Jackson ImmunoResearch Laboratories, USA). Briefly, polystyrene plates were coated 
overnight at room temperature with 100 µl per well of the primary antibody diluted (final 
concentration: 1.2 mg/l) in carbonate-bicarbonate buffer (0.05 M). The plates were washed 
four times with phosphate-buffered saline (PBS) with 0.5% Tween20 between the 
incubations. All samples were titrated against a six-fold serially diluted standard, ranging 
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from 3.125µg/l to 100µg/l. The samples, the standard dilutions and a blank (PBS with 0.5% 
Tween20) were added in duplicate and incubated overnight at room temperature. The alkaline 
phosphatase-conjugated antibodies (final concentration: 0.3mg/l) were added and incubated 
for 2 hours. p-Nitrophenyl phosphate dissolved in Diethanolamine buffer (Sigma-Aldrich, 
USA) was used to develop the plates and the absorbance was read at 405 nm on an ELISA 
microplate reader (Molecular Devices, USA). 
3.3 HLA TYPING 
3.3.1 HLA imputation using high-resolution SNP  
Imputation of HLA alleles was performed using high-resolution SNP data and two 
independent imputation pipelines, HLA*IMP02 (85) and SNP2HLA(86). HLA*IMP02 was 
carried out using a European reference panel and absolute posterior probability (Q2) ≥ 0.7 
was used as the cut off for the HLA- B, HLA-DRB1 and HLA-DQB1 analyses.  
 
For SNP2HLA, the Type 1 Diabetes Genetics Consortium dataset reference panel was used 
to perform the imputation of HLA types, polymorphic amino acid positions and SNPs. The 
minor allele frequency cut off was set at 0.5% and info score at ≥ 0.5. In total, 8404 
variants, including 7125 SNPs, 1042 amino acid polymorphisms, one hundred and forty-
five 4-digit resolution HLA alleles and ninety-two 2-digit resolution HLA alleles were 
retained for further analysis.  
3.3.2 Molecular-based HLA typing 
For verification of imputation results, a total of 767 Swedish IgAD samples were typed for 
HLA-B, HLA-DR and HLA-DQ using PCR-SSP (87) in 2-digit resolution according to the 
manufacturer’s instructions (Olerup SSP AB, Stockholm, Sweden).  
In addition, 150 IgAD samples and 25 control samples were typed at a 4-digit resolution 
using sequence-based typing (SBT) method as described previously (88). 
3.4 EXOME SEQUENCING  
Exome sequencing and the pipeline for analysis were performed as described (89). In brief, 
captured libraries were generated by ligation-mediated PCR. The fragments were 
hybridized using the Agilent SureSelect Human All Exon 50 Mb Kit (Agilent Technologies 
Incorporated, USA). Subsequently, each captured library was loaded onto an Illumina 
Hiseq2000 sequencer (Illumina Incorporated, USA) according to the manufacturer’s 
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protocol. The high-throughput sequencing was performed to acquire the desired average 
sequencing depth.  
3.5 GENOME-WIDE ASSOCIATION STUDY 
All of the genotyping arrays were carried out using the Omni chips developed by Illumina, 
Inc. (Illumina Incorporated, USA) according to the manufacturer’s instructions. IgAD cases 
were genotyped on the Omni1-Quad and Omni2.5 chips in Genentech Inc, CA, USA and the 
Mutation Analysis Core Facility at the Karolinska University Hospital, Stockholm, Sweden. 
Swedish controls were genotyped on Omni-Quad 1 (45) and the Swedish twinGene controls 
(82) were genotyped using the Omni Express chip.  All SNPs were mapped to build hg19 
coordinates using liftOver and the strand, alleles and positions were updated according to the 
strand data mapped to hg19 (90).  
3.6 SEQUENCING OF THE MHC REGION 
In order to search for new polymorphisms associated with IgAD development in the MHC 
region, we sequenced ten samples (5 IgAD patients and 5 controls) who carried the whole 
ancestral 8.1 haplotype in a homozygous form, by high-throughput sequencing, according to 
the protocol described previously (88). To obtain the complete MHC sequence of these 
samples, those regions with an average depth lower than four reads were defined as gaps and 
re-sequenced by Sanger sequencing.  For Sanger sequencing, specific primers pairs were 
designed by using PRIMER3 Input version (0.4.0) software (http://frodo.wi.mit.edu/). 
One hundred and fifty ng of genomic DNA was added to a final volume of 30µl of reaction 
mix containing the primers (0.4 mM), dNTPs (250uM), MgCl2 (2.5 mM) and 0.8 units of 
enzyme (GoTaq® DNA Polymerase, Promega).  In order to amplify the intergenic regions, a 
total of 3 different PCR programs were performed according to the DNA sequence 
characteristics (%AT or %GC): a) Standard PCR (94ºC for 2 minute (min); 30 cycles: 94ºC 
for 15 second (s), 60ºC for 30 s and 72ºC for 1 min, final elongation: 72ºC for 4 min; b) 
Touch-Down PCR (94ºC for 5 min; 30 cycles: 94ºC for 30 s, 66ºC for 30 s and 58ºC for 12 
min, final elongation: 58ºC for 30 min), the annealing temperature was decreased 0.3 ºC 
every cycle. c) High GC content – Touch down modified PCR (94ºC for 5 min; 40 A cycles: 
94ºC for 30 s, 70ºC for 30 s and 72ºC for 40 s; 15 B cycles 94ºC for 30 s, 58ºC for 30 s and 
72ºC for 40 s, final elongation: 58ºC for 5 min, the annealing temperature was decreased 0.3 
ºC every A cycle, the annealing ramp was set to 33% of the speed and the elongation ramp 
was adjusted to 30% of the speed. The size of all fragments was confirmed by electrophoresis 
in 0.8% agarose gel and the specific band was sliced follow by extracted with Qiaquick gel 
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extraction kit (QIAGEN, Hilden, Germany) and subsequently sent for Sanger sequencing to 
Macrogen Inc. All the sequences were aligned to the COX ([RRID: CVCL_E534], being 
homozygous for HLA-B*0801-DRB1*0301-DQB1*0201 (91)) published sequence using 
ClustalW software (http://www.ebi.ac.uk/Tools/msa/clustalw2) (92, 93).  
3.7 BIOINFORMATICS AND STATISTICAL ANALYSIS 
3.7.1 Sub-classification of population cohort and association analysis 
The analysis was initiated by comparison of individuals carrying at least one MHC risk allele 
(HLA*B0801-DRB1*0301-DQB1*0201 or HLA-DRB1*0701-DQB1*0202 or HLA-
DRB1*01-DQB1*0501) with individuals lacking a risk allele. The significantly different 
variants in the sample cohort were then filtered with the control cohort and only unique 
variants in the case comparison were considered to have an association with IgAD. The same 
strategy was applied in order to investigate and verify the signal by using the cohort with at 
least one HLA*B0801-DRB1*0301-DQB1*0201 risk haplotype (54% of IgAD individuals). 
The analysis was first performed by comparing all individuals without HLA*B0801-
DRB1*0301-DQB1*0201, followed by a comparison of individuals lacking all risk alleles.  
In the subsequent analysis, cohorts homozygous for HLA*B0801 HLA-DRB1*0301 HLA-
DQB1* 0201(68 IgAD and 123 controls), HLA-DRB1*0701 HLA-DQB1*0202 (7 IgAD and 
30 controls) and HLA-DRB1*01 HLA-DQB1*0501 (34 IgAD and 68 controls) were selected. 
In addition, we also investigated cohorts homozygous for a single allele, i.e., HLA*B0801, 
HLA-DRB1*0301, HLA-DRB1*0701 and HLA-DQB1*0501. 
χ2 tests of association for genotypes in each cohort were performed independently, using only 
variants that overlapped between the arrays. Variants reaching genome-wide significance (P 
< 5x10
-8
) were considered as being significantly associated with IgAD. In addition, variants 
with P < 2x10
-7
, and FDR< 0.05 were considered to show suggestive association with IgAD. 
3.7.2 Gene-based association analysis in different subgroups 
The GCTA-fastBAT software was used to analyze gene-based associations (94). A total of 
24125 genes including 1522 miRNA genes from the hg19 reference were included in the 
analysis. MHC genes were excluded to prevent an LD effect. The gene region was set at + 50 
kb from both 3’ and 5’ UTR of the genes. The LD cut off was set at 0.9. Non-MHC genes 
that had a minimum five SNPs within the regions with a total P<2 x10
-6 
were 
considered to be significant; while a total of P < 2 x10
-4 
were regarded as showing a 
suggestive association with IgAD. 
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3.7.3 Linkage disequilibrium proxy analysis of associated variants 
LD proxy analysis was performed using LDlink software (95), and only the European 
population (EUR) was selected for the analysis. R
2
 > 0.9 and D' > 0.9 were used as cut-offs. 
3.7.4 Pre-imputation filtering 
Prior to imputation, we used Genotype Harmonizer (96) to standardize the strand alignments, 
as well as the format for all arrays using the 1000 Genomes Project Phase 3 integrated variant 
set as a reference. In addition, variants with a genotyping rate <97% and evidence of 
deviation from Hardy-Weinberg equilibrium (HWE) in controls (P < 1x10
-6
) were removed.  
3.7.5 Imputation of missing genotypes in the MHC region and association analysis 
MHC region imputation was performed using Impute2 (97). Only samples and controls with 
a high confidence HLA classification proceeded to imputation of MHC regions from chr6: 
28.3 Mb to chr6: 33.8 Mb (total 180,123 SNPs) using the 1000 Genomes Project Phase 3 
integrated variant set release in NCBI, with build hg19 coordinates used as the reference 
panel. Cases and controls were imputed together; using only genotyped variants that 
overlapped across all the arrays. Genotypes were imputed in 1 – 1.5 MB chunks with the 
effective size of the population of 20,000. Additionally, 80 haplotypes as templates when 
phasing observed genotypes were used. A total of 30 Markov chain Monte Carlo (MCMC) 
iterations were performed where the first 10 MCMC iterations were discarded as burn-in.  
The quality control (QC) was set as MAF > 0.5%, info score > 0.5 and calling threshold > 
0.9; a total of 44857 variants passed the filtering stage and were included in the analysis. The 
thresholds for variant calling for each were set at 97%. In addition, the evidence of deviation 
from HWE (P< 1x10
-6
) in controls was set. A logistic regression model was applied to test 
for the association and significantly associated HLA types were used as covariates in the 
conditional analysis (Plink (1.07 (98)). Variants reaching genome-wide significance (P < 
5x10
-8
) were considered as being significantly associated with IgAD. 
3.7.6 Family-based association analysis 
Family association analysis was performed to assess susceptibility to IgAD using a family-
based association test (FBAT) (99, 100). Only HLA alleles with a minimum of ten 
informative families without Mendelian errors were included.  Since our dataset contains 
multiple siblings in a family as well as various families in a pedigree, the test statistics were 
computed using the empirical variance, as described in Lake et al. (101).  The single-locus 
analysis was conducted to test the association of IgAD with the classical HLA alleles using 
the additive genetic model. In addition, the multiple marker haplotype test was performed for 
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tightly linked HLA-DR and HLA-DQ loci. The direction and frequency of transmission were 
indicated by the Z statistic (Z score) and p-values. 
3.7.7 Estimation of increased risk over population prevalence to siblings due to 
disease susceptibility HLA genes  
The attributed risk analysis due to specific HLA alleles for IgAD development was based on 
the formula developed by Risch (102). The identity-by-descent (IBD) of all sibling pairs were 
calculated using the GENIBD program in the Statistical Analysis for Genetic Epidemiology 
(S.A.G.E) package (103). The allele frequency in the Swedish population was extracted from 
an allele frequency database (104). A lack of MHC recombination between HLA-DR and 
HLA-DQ was assumed in the calculation. The recurrence risk for siblings with IgAD was set 
at 50 according to a previous report (105).  
3.7.8 MHC recombination analysis 
The MHC region of six crossover samples, including three HLA-DRB1*0301-HLA-
DQB1*0201 samples without HLA-B*0801 and three samples with HLA- B*0801 only 
(without DRB1*0301-HLA-DQB1*0201) were sequenced using high-performance deep 
sequencing. The possible crossover layover in the class III region (the region between 
HLA-B and HLA-DRB1) were examined against COX, HLA-B*0801 DRB1*0301-HLA-
DQB1*0201 homozygous control and HLA-DRB1*0301-HLA-DQB1*0201 heterozygous 
control using fine mapping SNP examination.    
Sequencing reads of 6 crossover samples and 10 homozygous samples (including COX) were 
aligned to hg19 using the Burrows-Wheeler Aligner (BWA ver: 0.7.10). The bam files from 6 
crossover samples were then used as input by samtools (version 1.2) phase to link 
heterozygous SNPs to haplotypes. Homozygous regions within these heterozygous 
haplotypes were also regarded as haplotypes. Ten homozygous samples were used as the 
control to call SNPs using Samtools software (ver1.2). The haplotypes of 6 crossover samples 
were filtered out if their SNPs were inconsistent with the controls, or if their length was less 
than 5 Kbp.  Only the haplotype from the ancestral COX haplotype remained after the 
filtering process. Subsequently, all the samples were linked to construct the crossover 
regions. The final region which contained the portion of the ancestral haplotype was 
determined as the shared region of these areas. 
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3.7.9 MHC segment-based analysis 
The GCTA-fastBAT analysis was performed to investigate the segment based association 
(94). The MHC region chr6: 28.3 – chr6: 33.8 was analyzed in 100 Kbp interval segments.  
In total, 242 MHC genes, including 12 miRNA genes from hg19 reference genes were 
included in the region. LD cut-off of 0.95 was set. 
3.7.10 Heritability estimation 
The genome-wide complex trait analysis-restricted maximum likelihood (GCTA-REML) 
software (106) was used to estimate variance explained within the MHC region using the 
IgAD cases and controls. The heritability of IgAD within the MHC was estimated in the 
Swedish IgAD cohort (n=44857 imputed genotypes) (106), using the first 10 eigenvectors as 
covariates in the model and adjusted for the disease prevalence in Sweden (1/600). 
3.7.11 Statistical Analyses 
All the statistical analyses were performed using Microsoft Excel 2010 (Microsoft, USA) and 
GraphPad Prism software (GraphPad, USA). Fisher exact tests and one-way analysis of 
variance (ANOVA) were used in paper I and paper II.  
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4 RESULTS  
4.1 REVERSAL OF IGAD IN CHILDREN 
4.1.1 Frequency of reversal of IgAD based on clinical record review 
A total of 654 children diagnosed with IgAD between 1992 and 2012 at one of five 
participating university hospitals were identified. The children were aged between 4 and 13 
years. Of these, 232 had follow-up testing results available (minimum interval 90 days) up 
to 31 January 2014. In order to assess the validity of using 4 years of age as the minimum 
age at which to reliably diagnose IgAD, the children were subdivided into three age groups 
(A: 4–4.99; B: 5–9.99; C: 10–12.99) based on the age at which they were first diagnosed 
with IgAD.  
Nine out of thirty-nine (23.1%) children who were identified to have IgAD at 4 years of age 
had a serum IgA level above 0.07g/L upon re-testing. The average age of reversal was 9.53 ± 
2.91 years. Additionally, 30 of the 131 (22.9%) children with IgAD identified between 5 and 
9.99 years of age had a serum IgA level which had returned to the normal range at an average 
age of 12.21 ± 3.43 years of age. However, only 4 out of 62 (6.5 %) children who were 
diagnosed at 10 – 12.99 years of age showed a reversal of IgAD during the follow-up 
period. The frequency of reversal was significantly higher for children who were identified 
to have IgAD prior to the age of 10. No significant differences in gender were observed in 
IgAD reversal at any age of diagnosis. 
4.1.2 BAMSE follow up study 
From previous findings, five out of the ten children with IgAD had normal serum IgA 
levels at 8 years of age (13). Fourteen serum IgA levels from the 16-year old follow up 
study were analyzed using ELISA and 8 of the 14 children (57.1%) showed an increase in 
serum IgA above the cutoff level. Out of the eight children, four children were found to 
have a normalized IgA level (serum IgA over 0.7 g/L), while four remained partially deficient 
(serum IgA level 0.07 – 0.7 g/L), giving a prevalence of IgAD in the BAMSE cohort of 
1:404 at 16 years of age. 
4.2 THE HIGHER FREQUENCY OF IGA DEFICIENCY AMONG SWEDISH 
TWINS IS NOT EXPLAINED BY HLA HAPLOTYPES 
4.2.1 Distribution of IgA concentration 
The mean IgA concentration was 2.38 g/L (Standard Deviation (S.D) = 1.03) for MZ twins 
and 2.56 g/L (S.D=1.17) for DZ twins. The difference was significant for the mean 
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concentration (t = − 7.8, P= 9.9 x10− 15) and the effect size (η2 = 0.0047) was extremely 
small. The sex-stratified means were 2.53 g/L for male MZ twins and 2.26 g/L for female 
MZ twins, as compared with 2.71 g/L for male DZ twins and 2.43 g/L for female DZ twins. 
By using one-way ANOVA, the mean serum IgA concentrations for male and female twins 
were found to be significantly different (P= 1.43 x10
− 43
). However, no significant 
difference in the concentration was observed in a time-of-sampling-dependent manner. 
4.2.2 Influence of HLA alleles on IgAD and IgA concentration 
4.2.2.1 Influence on IgAD 
Comparison of HLA haplotypes was made between the twin study population (based on 
imputation of HLA types from high-resolution SNP data) and data from approximately 40 
000 individuals from the National Swedish Bone Marrow Donor Registry (Tobias Registret 
http://www.tobiasregistret.se). There was no difference in the frequency of HLA alleles in 
the twin cohort compared with a national population cohort. In addition, the HLA types of 
the MZ IgAD twins did not show significant differences when compared with the DZ twins. 
4.2.2.2 IgA concentration 
ANOVA was used to study the influence of individual HLA alleles on the IgA 
concentration. For MZ twins, IgA concentrations from only one twin from each twin pair 
were used, while IgA concentrations from both DZ twins were used. The IgAD associated 
HLA alleles A*01, B*08, B*13, B*14, DQB1*05, DRB1*01 and DRB1*07 were 
investigated. In addition, the protective alleles HLA B*07 and DRB1*15 (34) were also 
studied. From the analysis, individuals with the HLA alleles A*01 (p =0.019), B*08 
(p=0.003), B*14 (p=0-042), DRB1*01 (p<0.001), DRB1*03 (p=0.011) and DQB1*05 
(0.038) were found to have a significantly lower mean IgA concentration. On the other 
hand, individuals who carried the HLA alleles B*07 (p=0.001), DRB1*15 and DQB1*06 
(0.01) were found to have an increased mean IgA concentration. There was no significant 
difference observed between individuals with or without the HLA alleles B*13, DQB1*02 
and DRB1*07.  
4.2.3 Exome sequencing of selected discordant MZ twins  
Exome sequencing was performed on two selected MZ twin pairs discordant for IgAD. 
However, no mutations or structural variants were found in the IgA deficient twin as 
compared to their sibling. 
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4.3 FINE MAPPING AND DEEP SEQUENCING OF THE MAJOR 
HISTOCOMPATIBILITY COMPLEX IDENTIFIES SUSCEPTIBILITY 
LOCI/VARIANTS FOR IMMUNOGLOBULIN A DEFICIENCY  
4.3.1 Estimation of heritability MHC effect  
The genome-wide complex trait analysis-restricted maximum likelihood (GCTA-REML) 
software (106) was used to estimate variance explained within the MHC region using a large-
scale case-control study (636 IgAD patients and 7798 controls). The heritability of IgAD in 
the Swedish patients in the MHC region was estimated to be 46% (standard error [S.E.] 
=2.9% with the first 10 eigenvectors as covariates in the model and adjusted with the disease 
prevalence in Sweden [0.167%]). 
4.3.2 Family association analysis and estimation of attributed risk due to disease 
susceptibility HLA genes  
Seventy-three multi-case families including 162 sibling pairs who had been followed up since 
1999 were included in the analysis. Strong associations were observed in HLA-B*08 (Z: 2.60; 
p=0.0094), HLA-DR*03 (Z: 2.98; p=0.0029) and HLA-DQ*02 (Z: 3.91; p=0.0001) while the 
strongest protection was seen in the HLA-DQ6 (Z:-2.69; p=0.0072) positive individuals, 
which was in agreeance with a previous finding (32).  We next determined the attributed risk 
due to this specific HLA ancestral allele for IgAD development using the identity-by-descent 
(IBD) of all sibling pairs based on the formula developed by Risch (102). Based on a total of 
31 affected sibling pairs where at least one sibling carried the risk haplotype (HLA- B*08-
DRB1*03-DQB1*02), the genetic effect due to this risk haplotype was 34.6%.  
4.3.3 MHC fine mapping and Haplotype association analysis in a large-scale case-
control study 
Three class I HLA genes (HLA-A, HLA-B and HLA-C) and five class II HLA genes (HLA-
DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1) were examined. Twenty-six 
4-digit HLA alleles were significantly associated with IgAD (p < 5 x 10
-8
) (Figure 3).  The 
strongest association signal was detected from HLA-DQB1*0201 (OR = 3.35, P= 1.13 × 
10
−78
) whereas the highest odds ratio (OR= 7.78, CI 95%, 5.335 – 11.34) was derived from 
HLA-DRB*0102. In addition, the multiple haplotype effect of the HLA- B*0801-
DRB1*0301-DQB1*0201 allele (OR = 3.59, P = 3.17 × 10
−82
) showed the strongest 
association with IgAD, while the secondary signal came from HLA-DRB1*0701- 
DRB1*0202 (OR = 1.84, P = 1.19 × 10
−9
). These results were consistent with previous 
findings (34, 107).  
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Because of the extensive LD nature and complexity of the MHC region, a conditional 
analysis was used to identify independent MHC haplotypes that may drive IgAD risk. The 
most significant associated alleles from HLA-B, HLA-DRB1 and HLA-DQB1 were in the 
model as covariates.  If any HLA alleles remained significantly associated, it would be 
included in the next model as a covariate until no HLA alleles would reach the stringent 
significant threshold (p < 5x 10
−8
).  Firstly, we used multiple logic regression analysis 
conditioned on the strongest risk haplotype in HLA- B, HLA-DRB1 and HLA-DQB1 alleles. 
The HLA-DPB1*1301 allele (OR = 1.84, P = 2.20 × 10
−9
) showed an independent risk 
separate from all known associated alleles. Further conditional analysis using HLA-
DPB1*1301 as a covariate did not show any other significant associated alleles. In addition, 
linkage graph analysis using the Disentangler software confirmed that the HLA-
DPB1*1301 signal is independent of the currently known susceptibility haplotypes for 
IgAD. 
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4.3.4 Long-range haplotype analysis 
One common long-range haplotype spanning the entire HLA class I and class II regions 
that was in strong association with IgAD risk in the Swedish population was observed, i.e. 
HLA-A*0101-C*0701-B*0801-DRB1*0301-DQA1*0501-DQB1*0201-DPA1*0201-
DPB1*0101 (F case = 0.091, OR = 4.07, P= 1.71 × 10
−31
). Further analysis of this long-
range haplotype showed that only in the presence of HLA-A*0101 (OR=0.488, P= 4.56 × 
10
−4
), HLA- A*0101-C*0701- B*0801(OR= 0.985, P= 0.957) or HLA-DRB1*0301-
DQA10501-DQB1*0201 (OR= 1.03,  P= 0.913) was this haplotype not associated with 
IgAD.  
4.3.5 MHC recombination analysis 
The MHC region of crossover samples from six patients, including three patients 
heterozygous for HLA-DRB1*0301-HLA-DQB1*0201 but without HLA- B*0801, and three 
samples heterozygous for HLA-B*0801 alone but without DRB1*0301-DQB1*0201, where 
the second haplotype has been shown to be neutral with regard to IgAD were examined. 
The possible crossover site was located in the class III region (between HLA-B and HLA-
DRB1) and was analyzed using the COX cell line (91) as a control. The haplotype blocks (5 
kbp/blocks) that were homozygous in COX, but heterozygous in the samples were 
considered ”ancestral blocks.” A region of approximately 110 kbp in length, which may 
contain the shared ancestral block for all the samples was identified. The chromosome is 
located at chr6:31997601-32107851, within the MHC class III region. The genes located 
within this region are C4B, CYP21A2, TNXB, ATF6B, and FKBPL.  
4.3.6 Complete sequencing of the MHC region  
The MHC region was completely sequenced and aligned to the COX cell line using the 
ClustalW software. In total, 473 SNPs and 3837 InDels variants were identified. Thirty-nine 
of these were located in exons, 74 in UTR’s, 1562 in introns and 2635 in the intergenic 
regions which have not been listed in either the dbSNP150 database (February 03, 2017 
release) or in the 1000 Genomes Project database (September 14, 2014 release) or the 
NHLBI-ESP project with 6500 exomes (June 07, 2013 release).  There was no significant 
difference observed in the new variants between IgAD patients and controls. 
4.3.7 MHC segment analysis and identification of the independent variants 
associated with IgAD 
A 100K bp segment-based analysis with an LD cut-off set at 0.95 was performed. The 
analysis included 8434 individuals in order to investigate the strongest association region for 
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IgAD within the MHC region. Interestingly, the strongest association was detected in the 
class III region, chr6: 32.1 – 32.2, P = 8.34 × 10
-110
 whereas rs1800625 produced the 
strongest signal (Pnominal = 4.80 × 10
-104
). The stepwise conditional analysis allowed us to 
identify three independent signals, including RNF5 (rs3130349), BTNL2 (rs1980493), and 
HCG23 (rs3117097) within the MHC region class III region that were associated with IgAD.  
4.4 DISTINCT NON-MHC GENE ASSOCIATIONS OF IGAD PATIENTS 
CARRYING DIFFERENT MHC RISK ALLELES   
4.4.1 MHC association analysis and multiple haplotype association investigations 
8,434 samples (636 IgAD and 7798 controls) passed QC and were included in the analysis.  
In the MHC haplotype analysis, the HLA-B*0801-DRB1*0301-DQB1*0201 haplotype 
showed the strongest association with IgAD (OR = 3.59, P = 3.17 × 10
−82
). The HLA-
DRB1*0701- DRB1*0202 (OR = 1.84, P = 1.19 × 10
−9
) and HLA-DRB1*0101- 
DQB1*0501 (OR = 1.41, P = 1.31 × 10
−4
) showed a weaker association with IgAD. The 
effect of HLA-DRB1*0102-DQB1*0501 was not possible to determine due to the low 
frequency in controls (F < 0.01). Therefore, combined signals of HLA-DRB1*0101 
DQB1*0501 and HLA-DRB1*0102-DQB1*0501 were investigated and showed a strong 
association signal HLA-DRB1*01-DQB1*0501 (OR = 1.84, P  = 3.90 × 10
−14
). However, 
the presence of HLA-B*0801 (OR = 1.32, P = 1.17 × 10
−1
) alone or HLA-DRB1*0301-
DQB1*0201 (OR = 1.32, P = 7.24 × 10
−2
) alone was not sufficient to confer susceptibility 
to IgAD. Similarly, the presence of the HLA-DRB1*0701 (OR = 1.06, P = 7.16 × 10
−1
) 
alone was not associated with IgAD. Since the HLA-DQB1*0202 is in complete linkage 
disequilibrium (LD) with HLA- DRB1*0701, it was therefore not possible to investigate the 
effect of HLA-DQB1*0202 without the presence of HLA- DRB1*0701. Similarly, the effect 
of HLA-DRB1*01 or HLA-DQB1*0501 alone could not be determined due to the low 
number of cases and controls.  
Haplotype linkage analysis showed that HLA-DQB1*0201 was in complete LD (100%) 
with HLA-DRB1*0301 and vice versa and HLA-DQB1*0202 had a 100% association with 
HLA-DRB1*0701. On the other hand, 74.7% of HLA-DRB1*0701 was linked to HLA-
DQB1*0202, whereas 24.7% was associated with HLA-DQB1*0303. In addition, 72% of 
the HLA-DRB1*0101 and 22.8% of the HLA-DRB1*0102 alleles were associated with 
HLA-DQB1*0501, while the remaining 5.2% were mainly associated with HLA- 
DRB1*0103 and DRB1*1001.  
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4.4.2 Analysis of the influence variants outside of the MHC region in IgAD patients 
homozygous for high-risk HLA alleles 
Based on the cross-comparison strategy, only one significantly associated non-MHC 
variant, rs4097492 (OR = 0.23, P= 7.63 x 10
−9
), an intronic variant of STXBP6 on 
chromosome 14 was detected in the IgAD cohort alone. Next, we analysed the individuals 
expressing at least one HLA*B0801-DRB1*0301-DQB1*0201 and compared these with 
individuals who do not carry HLA*B0801-DRB1*0301-DQB1*0201 (but we did include 
individuals carrying other risk haplotypes), and did not detect any significant variants.  
However, if we only compared these with individuals not carrying a risk haplotype, the 
identical non-MHC variants, rs4097492 (OR = 0.22, P= 4.01 x 10
−8
) passed the genome-
wide threshold (P < 5.0 x 10
−8
).   
In the HLA-DRB1*0701-DQB1*0202 homozygous cohorts, we identified one significant (< 
5x 10
−8
) and two suggestive variants (< 2 x 10
−7; FDR ≤ 0.05). The peak novel variant was 
rs2133282 (OR = 33, P= 3.97 x 10
−8
; FDR= 0.02), an intergenic variant located between 
NOX3 and ARID1B on chromosome 6. Rs3917325 (OR = 59, P= 1.57 x 10
−7
; FDR< 0.05), 
an UTR3 variant of IL1R1 on chromosome 2 and rs257945 (OR = 38.67, P= 1.14 x 10
−7
; 
FDR= 0.05), an intergenic variant located between NEDD1 and RMST on chromosome 12 
were found to be suggestively associated.  
For the HLA-DRB1*01-DQB1*0501 homozygous individuals, rs10399952 (OR= 15.4, 
P=5.05x10
−9
), a variant of FMO1 on chromosome 1 was found to be significantly associated 
with IgAD. However, we did not detect any strong signal (< 5x 10
−8
or < 2 x 10
−7
) based on 
the analysis method in the HLA-B*0801-DRB1*0301-DQB1*0201 homozygous cohort.  
4.4.3 Analysis of influence genes using gene-based analysis in different subgroups 
In order to enhance the detection power, the data was investigated using a gene-based 
association analysis. With the enhanced detection method, CD40 (P = 6.89 x 10
−5
) on 
chromosome 20, with 29 SNPs in the analyzed gene region, was found to be potentially 
associated with IgAD in patients homozygous for HLA-B*0801-DRB1*0301-DQB1*0201. 
DHX38 (P = 8.60 x 10
−5
), a novel inhibitor of protein phosphatase 4 (108) located on 
chromosome 16 with a total of 14 SNPs in the analyzed region, was shown to be weakly 
associated with IgAD patients homozygous for HLA-DRB1*01-DQB1*0501.  
A total of 7 gene regions were identified, showing suggestive association with IgAD in the 
patients who did not carry any of the major MHC susceptibility alleles. Most (6 out of 7) of 
these genes were associated with DNA repair or autoimmune disease. The associated genes 
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included B3GNT6 (P = 2.09 x 10
−6
), TNFRSF13B (TACI) (P = 1.12 x 10
−4
), GIMAP5 (P = 
1.9 x 10
−4
), SFPQ (P = 1.00 x 10
−4
), OXA1L (P = 1.18 x 10
−4
), TFAP2E (P = 6.99 x 10
−5
), 
and ZMYM4 (P = 1.07 x 10
−4
). The locations of all the identified genes identified by two 
different methods are shown in the chromosome ideogram according to the MHC 
susceptibility groups (Figure 4).  
 
Figure 4. Chromosome ideogram for all identified susceptibility genes/locus in the patients with different 
MHC risk alleles. Chromosome ideogram was generated using the Phenogram software (109). Blue 
circle: location of genes/locus associated with the HLA-B*0801-DRB1*0301-DQB1*0201 homozygous 
cohort; Green circle: location of genes/locus associated with the DRB1*01-DQB1*0501 homozygous 
cohorts; Red circle: location of genes/locus associated with the DRB1*0701-DQB1*0202 homozygous 
cohorts; Black circle: location of genes/locus associated with patients carrying no MHC susceptibility 
genes. Pink circle: location of genes/locus associated with patients carrying at least one MHC 
susceptibility genes. The MHC region is highlighted in purple box. Coloured region indicated the 
cytogenetic band on each chromosome according to the predefined setting, based on ideogram 
documented in the UCSC database (110). 
 
  35 
5 DISCUSSION AND FUTURE PERSPECTIVES 
Overall, this thesis aimed to identify the genetic basis of the most common primary 
immunodeficiency disorder in the world. Before commencing the genetic analysis, we first 
verified and fine-tuned the current definition of IgAD in order to have a better sampling 
criteria for subsequent projects. To date, several studies have shown that compared to adults, 
there is a relatively high proportion of IgAD in pediatric patients that are transient in children 
over the age of four (72, 111-115). In paper I, our study was the first to evaluate reversal of 
IgAD among children. We showed that around 22.9% (39 out of 170) children who were 
diagnosed as having IgAD prior to 10 years of age had an increase in their serum IgA level 
with increased age. The reversal was highly significant as compared to those diagnosed after 
10 years of age. This observation indicated that more than one-fifth of Swedish children 
might have delayed ontogeny of their IgA system. Hence, it may be too early to establish a 
diagnosis of IgAD using a serum level of 0.07g/L as a cutoff in children. In addition, in the 
BAMSE follow up study, more than 57.1 % (8 out of 14) of the children had reversed their 
IgAD status during a follow-up period of 12 years. The percentage of reversal was more than 
twice as high (57.1% vs. 22.9%) in this cohort as compared to children with a suspected 
disease based on gastrointestinal symptoms, celiac disease, etc. Since the BAMSE cohort 
represents a “healthy” control group, this observation indicated that reversal of the serum IgA 
level may potentially be higher in asymptomatic individuals. 
Next, we initiated a twin study (paper II). Twins, in particular MZ twins discordant for a 
given disease, provide a unique opportunity to study the complex interplay of genes and 
environment in disease susceptibility (116). To date, there are six studies evaluating serum 
IgA concentrations in twins, of which three studies were case reports (117-119).  Two studies 
quantified and compared the level of serum IgA in MZ and DZ twins (42, 43). The first paper 
suggested a genetic influence on serum IgA concentrations (120) whereas the second study 
showed that the serum IgA concentration was influenced by a combination of genetic and 
environmental factors (121). The last report focused on susceptibility genes for 
immunoglobulin deficiencies in MZ twins discordant for type 1 diabetes (122).  Pairwise 
concordance for IgA was 50% in the MZ twins, thus markedly higher as compared with 
randomly paired controls.  
We reported that the prevalence of IgAD was 1:241 in MZ twins and 1:198 in DZ twins, 
which was markedly higher than that in the healthy Swedish adult population (1:600). 
However, the associated HLA haplotypes were not significant in comparison with 40 000 
Swedish healthy controls. This observation suggested that the genetic contribution by the 
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MHC region might be similar.  The risk-conveying HLA alleles A*01, B*08, B*14, 
DRB1*01 and DQB1*05 were associated with significantly lower serum IgA concentrations 
in the twin cohort. Our report is the first to describe the disease risk and protective MHC 
alleles that influence serum IgA levels. In addition, exome sequencing from two MZ twin 
pairs discordant for IgAD revealed no differences between the siblings. Furthermore, the 
heritability of 35% for IgAD suggests a genetic influence.  
We further investigated the role of genetics in IgAD by performed a comprehensive 
examination within the MHC region to study the IgAD risk (paper III) and studied the 
association/interaction of the non-MHC genes in individuals who carry different MHC 
haplotypes (paper IV). The majority of the twin cohort participants (77.2%) and more than 
1100 IgAD patients and controls were also included in the study using fine-mapping 
strategies.  
In general, fine-mapping strategies have confirmed the major associated locus reported by 
serotype analysis within a particular MHC locus in most autoimmune disorders. In addition, 
the strategies have provided the opportunity to investigate and determine specific allelic 
variants as well as independent variants in different HLA classes that are associated to the 
diseases. For example, for multiple sclerosis (MS), SLE and T1D, the strongest association 
was detected within with the MHC class II locus. However, there are also weaker 
associations within the class I as well as class III regions being fine-mapped (123-125). In 
addition, HLA-DPB1*17, in MHC class II, was identified being the most significant 
haplotype associated with dermatomyositis in Asian population (126). 
By applying similar strategies, we confirmed the primary association signal from the HLA-
B*0801-DRB1*0301-DQB1*0201 haplotype (OR = 3.59, P = 3.17 × 10
−82
) and a secondary 
signal was observed from the HLA-DRB1*0701- DRB1*0202 haplotype (OR = 1.84, P = 
1.19 × 10
−9
). This data is in agreement with previous findings (32, 34). In addition, HLA-
DPB1*1301 (OR = 1.84, P = 2.20 × 10
−9
) was shown to be an independent risk signal and 
concurred with previous observations (107). 
Extensive LD has been a significant obstacle to the investigation of causal genes within the 
MHC region. The recombination rate within the MHC is lower than the genome-wide rate 
determined by sperm typing (127). The rate was predicted to be less than 1 % per Mega 
basepair (bp) in each meiosis (128, 129). The same report showed that the recombination rate 
within the class II region was 0.74% and 0.94% within the class III region (128). However, 
only one unique case of recombination within the DRB1-DQA1-DQB1 locus has been 
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observed (130). Investigation of the recombination between loci may provide clues to the 
location of the IgAD predisposing genes. We thus examined the MHC region in crossover 
samples from patients, and identified a region approximately 110 kb in length in MHC class 
III as shared ancestral block. However, further analysis with controls carrying the ancestral 
8.1 haplotype did not show any differences.  In addition, there was no significant difference 
noted after verification with complete sequencing of the regions (including 91 newly 
identified variants in the shared ancestral block). This observation suggested that the ancestral 
block may not contain independent IgAD predisposing genes. The MHC class I and II genes 
themselves may carry the susceptibility. Since not all individuals who carry MHC risk 
haplotypes suffer from IgAD,  susceptibility to IgAD may be due to a combined effect owing 
to an interaction within MHC genes, as well as the interaction of an MHC-encoded 
susceptibility allele with a disease contributing non-MHC gene. 
Fine mapping strategies have identified multiple MHC Class III variants significantly 
associated with autoimmune diseases, including the association to variant rs2516489 which is 
located between the MICB and LST1 genes in MS (125). An independent association signal 
located at the upstream of NOTCH4 in MHC class III region was determined by a stepwise 
meta-analysis of sizeable European SLE cohort (131). Additionally, an association signal of 
SKIV2L in the MHC class III region has also been suggested involving in susceptibility to the 
pathogenesis of SLE (132).   
In addition, Goudey et al. reported 20 significant epistatic signals within the MHC which 
contribute to the genetic architecture of celiac disease (133).  The majority of the strongest 
signal was located in the MHC class III region, over 1Mb upstream of the HLA-
DQA1 and HLA-DQB1 risk loci, whereas the strongest signal corresponded to genes in the 
MHC class III region, in particular, PRRC2A and GPANK1/C6orf47 (133). Celiac disease has 
been reported to be strongly associated with IgAD, with up to a 15-fold increase in the 
prevalence of IgAD observed among both children and adults with CD (12).  The 
identification of strong association regions within MHC class III that likely play a role in the 
genetic epistasis in IgAD suggests a potentially shared genetic predisposition with celiac 
disease. 
By using segment-based analysis in the fine-mapping strategies, the strongest association was 
detected in the class III region, which contains 14 genes, with rs1800625 producing the 
strongest signal (P = 4.80 × 10
-104
). The variant, rs1800625 is located in the promoter region 
of the advanced glycosylation end product-specific receptor (AGER). The gene is involved in 
innate immune mechanisms as well as mediating interactions of advanced glycosylation end 
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products which play a crucial role in regulating the production/expression of TNF, as well as 
oxidative stress (134, 135). TNF has previously been shown to be involved in the regulation 
of IgA production (136, 137).  In addition, three independent signals including variants in 
RNF5 (rs3130349), BTNL2 (rs1980493), and HCG23 (rs3117097) within the MHC class III 
region has been identified. Rs3130349 has been reported to be linked to age-related macular 
degeneration (AMD) (138, 139). Interestingly, in AMD patients, overactive IgA responses 
and increased levels of serum IgA have been observed (140). The BTNL2 variant rs1980493 
has previously been shown to be associated with autoimmune diseases including autoimmune 
thyroid disease, T1D and SLE (141-143) and IgAD is overrepresented among all these 
autoimmune disorders(12). This observation provides another piece of evidence of a potential 
shared genetic predisposition between IgAD and autoimmune diseases.  
In addition to identifying independent variants, GWAS and MHC region fine-mapping 
studies allowed the analysis of epistatic interactions between genes. Multiple studies have 
reported the epistatic interactions between MHC and non-MHC alleles in autoimmune 
diseases, including T1D (144-146), GD (147-150), RA (151), SLE (146), ankylosing 
spondylitis (AS) (152), psoriasis (153) and MG (154). For example, the most significant 
epistatic interaction signal was identified between the MHC region and cytotoxic T 
lymphocyte antigen 4 (CTLA4) in the European SLE patients (155). CTLA4 gene is 
upregulated in activated T cells (interacting with antigen-presenting cells (APCs)) and 
transmits an inhibitory signal to T cells (156). This finding indicated that proper antigen 
presentation and T cell activation is essential in the pathogenesis of SLE (155). In addition, 
the epistatic effects of MHC and non-MHC loci may also help to elucidate the mechanistic 
basis of the disease. For instance, individuals who carry variants in ERAP1 showed an 
increased risk of psoriasis when they also carried a HLA-C risk allele (153). Similarly, 
epistatic effects were also observed for ankylosing spondylitis (AS), where loss-of-function 
variants of ERAP1 reduced the risk of AS in individuals who carried the HLA-B*27 and 
HLA-B*4001 haplotypes, but not in individuals carrying other risk haplotypes (152). Animal 
studies have shown that ERAP1 regulates the cleavage of relevant epitopes so that the 
epitopes can be presented by the HLA-B*27 molecule (152). This observation suggested that 
specific epitope have to be cleaved by ERAP1 in order to be efficiently presented. This step 
may be critical for identification of specific triggers for autoimmune diseases.  
Our study is the first to investigate the interaction between the MHC alleles with non-MHC 
genes in IgAD. Altogether, we identified 14 variants/genes that are potential susceptibility 
loci for IgAD in different cohorts, including one for all major risk alleles, one from HLA-
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B*0801-DRB1*0301-DQB1*0201, three from the HLA-DRB1*0701-DQB1*0202 cohort, 
two from HLA-DRB1*01-DQB1*0501 and seven in the patients who do not carry any 
susceptibility MHC alleles. The majority of the identified genes and variants were associated 
with an immune function or autoimmune disease, including the known IgAD associated 
genes, TNFRSF13B/TACI (56, 57). TACI gene was detected in patients who did not carry any 
risk alleles. On the other hand, our results show that CD40, which is involved in the 
regulation of IgA class switching (157), is suggestively associated with IgAD in the patients 
who are homozygous for the HLA-B*0801-DRB1*0301-DQB1*0201 haplotype. We also 
identified a UTR variant in the IL1R1 gene which was associated with the IgAD in the HLA-
DRB1*0701-DQB1*0202 cohort. Interestingly, multiple loci in IL1R1 have been reported to 
be associated with IgA nephropathy (IgAN) (158), a disease which is linked to 
overproduction of IgA.  This finding suggests that IL1R1 may potentially play a role in IgA 
production. 
As the clinical presentation of IgAD varies, ranging from asymptomatic to highly 
symptomatic patients, observation of differences in the non-MHC association in IgAD 
depending on the MHC risk alleles is not unexpected. The findings open up interesting 
perspectives for future research.  
GWAS has been highly successful in the identification of genetic variants associated with 
complex human disorders. However, GWAS generally captures only a few percents of the 
estimated heritability for these complex diseases (159). Application of a conservative 
threshold for the association may miss some causal SNPs. In addition, it has been postulated 
that the missing heritability could partially be explained by epistasis or rare variants (160). A 
well-selected cohort may improve the discovery of missing causal signals (160).  In our 
study, selected patients and controls enabled us to identify novel association signals within 
and outside the MHC regions. A similar approach has been adopted previously in other 
autoimmune diseases including AS and psoriasis, where the interaction between the HLA-
B*51 allele and HLA-C loci and ERAP1 and HLA-B*27, respectively were identified (161-
163). In contrast, these different strategies missed the detection of several genes which were 
previously implicated in the susceptibility to IgAD, including PVT1, ATG13-AMBRA1, AHI1, 
CLEC16A and mir-6891 (46, 164).  In addition, the relatively smaller sample size in our 
selected cohort also limited our detection power in genes with a modest effect, although 
multiple strategies were employed.  
In summary, this thesis has helped to advance our knowledge of the genetics of IgAD, the 
most common primary immunodeficiency disorder in the western world. In addition, this 
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study has also helped to refine the diagnostic definition of IgAD. Given the variable clinical 
presentation of IgAD, our findings, including 14 associated variants/genes in different cohorts 
outside the MHC region, four genes in the MHC class III region and three major MHC 
haplotypes, suggests that in contrast to other monogenic primary immunodeficiency diseases, 
IgAD is most likely to be a multi-complex rather than a pure monogenic disease, further 
evaluation of which represents the “next generation” in the genetics of immunodeficiency 
diseases. Further advancement in genetic studies may lead to a new definition of the disease 
based on the genetics of the individual. In addition, sub-categories of the disease may be 
identified. Currently, screening and evaluation for IgAD in the Asian population is ongoing to 
verify whether Caucasian haplotypes are the major risk factors for the disease. Additionally, 
whole genome sequencing of multi-case families is progressing in order to further enhance 
our understanding of the genetics of the disease. In addition, further work such as protein-
protein interaction investigation, gene knock-in/out and expression testing are planned to 
validate the functional role of the novel associations described in the present thesis. It may 
also form the basis for understanding the cellular pathways involved in the pathogenesis of 
the disease, paving the way for potential supportive or even curative therapy for affected 
patients.  
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6 CONCLUSIONS 
 In Paper I, the rate of reversal of IgAD in children who were diagnosed before the age 
of 10 is significantly high. The minimum age of four years to make a diagnosis of 
IgAD with a 0.07 g/L as cutoff may need to be altered to prevent a premature diagnosis 
of IgAD. A definitive diagnosis of IgAD should not be made before the early teens.  
 
 In Paper II, the MHC haplotypes were shown not to be the factor responsible for the 
increased frequency of IgAD in twins. However, the MHC haplotypes may play a role 
in regulating serum IgA concentrations in the twin cohort. A heritability of 35% was 
demonstrated and suggested that genetic influences are important for IgAD.  
 
 In Paper III,  novel independent HLA haplotypes, as well as independent gene variants 
associated with IgAD disease risk within the MHC were identified. Complete 
sequencing of the ancestral 8.1 haplotypes identified a large number of novel genetic 
variants and may provide valuable information for the investigation of other MHC 
associated diseases.  
 
 In Paper IV, the development of IgAD may be variable depending on the presence of 
different genes within selected MHC susceptibility haplotypes which interact with the 
potential disease-causing non-MHC genes. Understanding the interaction between MHC 
and non-MHC genes/protein may facilitate future identification of the etiology of IgAD. 
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